Boston Scientific (BSX) Tops Q1 EPS by 4c; Boosts FY16 Outlook

Go back to Boston Scientific (BSX) Tops Q1 EPS by 4c; Boosts FY16 Outlook

Boston Scientific (BSX) PT Raised to $26 at Needham & Company

April 27, 2016 2:13 PM EDT

Needham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on Boston Scientific (NYSE: BSX) to $26.00 (from $22.00), saying Q1 marks and inflection point for growth and margins.

Matson commented, "BSX beat consensus 1Q16 revenue and EPS by a wide margin.... More

Boston Scientific (BSX) PT Raised to $23.50 at Evercore ISI

April 27, 2016 1:02 PM EDT

Evercore ISI analyst Vijay Kumar raised estimates and his price target on Boston Scientific (NYSE: BSX) to $23.50 (from $21.50) due to market multiple expansion. The firm maintained a Buy rating.

FY16 EPS was raised from $1.06 to $1.11 mainly due to higher organic revenue growth (mainly from... More

Boston Scientific (BSX) Gains Following Strong Results, Outlook

April 27, 2016 9:53 AM EDT

Boston Scientific (NYSE: BSX) is strong out of the gate following better-than-expected earnings and a raised outlook. Shares last traded up 8.9%.

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the... More